Dr Anna Chioti nominated as a member of the Scientific Committee of the Innovative Medicines Initiative 2 Joint Undertaking
Dr Anna Chioti, Director ad interim of LIH’s Department of Population Health, was designated among a list of candidates proposed by the States Representatives Group of the Innovative Medicines Initiative (IMI) to become a member of the Scientific Committee of the IMI 2 Joint Undertaking.
Starting from 1st October 2016, she will hold this important function for two years, which will provide an opportunity for Luxembourg to be at the forefront of strategic research priorities for EU public-private partnerships (PPPs).
IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. It is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
IMI 2 Joint Undertaking is the second programme of IMI, launched in 2014 for ten years. This programme intents to develop next-generation vaccines, medicines and treatments, such as new antibiotics. One of its key objectives is to improve the current drug development process by providing support for the development of tools, standards and approaches to assess efficacy, safety and quality of regulated health products.
IMI 2 will build on the successes and lessons learnt under the first phase IMI 1. It will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises, patient groups and regulators in collaborative projects to tackle Europe’s growing health challenges and secure the future international competitiveness of Europe’s pharmaceutical industry.
The Scientific Committee in which Dr Chioti now takes part acts as an advisory body of the IMI 2 Joint Undertaking. It advises the Governing Board by giving strategic science-based recommendations. The Scientific Committee is composed of a balanced representation of worldwide-recognised experts from the European Union or EU-associated countries working in academia, industry or regulatory bodies.
With her internationally recognised expertise in clinical research, Dr Chioti is a valuable member for the committee. Dr Chioti readily accepted her nomination. ‘It is a great pleasure and honour for me to be part of this committee for the next two years. I am looking forward to fruitful exchanges and collaboration with other European experts and key opinion leaders from various fields’, she says.